Sage Therapeutics Inc. buy Royal Bank of Canada
Start price
13.03.23
/
50%
€42.33
Target price
13.03.24
€56.02
Performance (%)
-56.77%
End price
14.03.24
€18.30
Summary
This prediction ended on 14.03.24 with a price of €18.30. Massive losses of -56.77% were the result for the BUY prediction by Royal_Bank_of_Canada. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Sage Therapeutics Inc. | - | - | - | - |
| iShares Core DAX® | -1,28 % | 4,21 % | 7,08 % | 64,25 % |
| iShares Nasdaq 100 | -3,34 % | -1,74 % | 26,18 % | 84,97 % |
| iShares Nikkei 225® | -4,29 % | -1,62 % | 44,32 % | 79,25 % |
| iShares S&P 500 | -2,31 % | -0,10 % | 20,82 % | 68,08 % |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Sage Therapeutics Inc. diskutieren
Sage Therapeutics, Inc. (NASDAQ: SAGE) was upgraded by analysts at Royal Bank of Canada from a "sector perform" rating to an "outperform" rating. They now have a $60.00 price target on the stock, up previously from $40.00.
Ratings data for SAGE provided by MarketBeat
In the thread Trading Sage Therapeutics Inc.
Die von Royal_Bank_of_Canada gewählte maximale Laufzeit wurde überschritten